BACKGROUND: Previous reports demonstrated that digitalis-like cardiotonic steroids (CTS) contribute to the pathogenesis of end-stage renal disease. The goal of the present study was to define the nature of CTS in patients with chronic kidney disease (CKD) and in partially nephrectomized (PNx) rats. METHODS: In patients with CKD and in healthy controls, we determined plasma levels of marinobufagenin (MBG) and endogenous ouabain (EO) and erythrocyte Na/K-ATPase activity in the absence and in the presence of 3E9 anti-MBG monoclonal antibody (mAb) and Digibind. Levels of MBG and EO were also determined in sham-operated Sprague-Dawley rats and in rats following 4 weeks of PNx. RESULTS: In 25 patients with CKD plasma, MBG but not EO was increased (0.86 ± 0.07 versus 0.28 ± 0.02 nmol/L, P < 0.01) and erythrocyte Na/K-ATPase was inhibited (1.24 ± 0.10 versus 2.80 ± 0.09 μmol Pi/mL/h, P < 0.01) as compared to that in 19 healthy subjects. Ex vivo, 3E9 mAb restored Na/K-ATPase in erythrocytes from patients with CKD but did not affect Na/K-ATPase from control subjects. Following chromatographic fractionation of uremic versus normal plasma, a competitive immunoassay based on anti-MBG mAb detected a 3-fold increase in the level of endogenous material having retention time similar to that seen with MBG. A similar pattern of CTS changes was observed in uremic rats. As compared to sham-operated animals, PNx rats exhibited 3-fold elevated levels of MBG but not that of EO. CONCLUSIONS: In chronic renal failure, elevated levels of a bufadienolide CTS, MBG, contribute to Na/K-ATPase inhibition and may represent a potential target for therapy.
BACKGROUND: Previous reports demonstrated that digitalis-like cardiotonic steroids (CTS) contribute to the pathogenesis of end-stage renal disease. The goal of the present study was to define the nature of CTS in patients with chronic kidney disease (CKD) and in partially nephrectomized (PNx) rats. METHODS: In patients with CKD and in healthy controls, we determined plasma levels of marinobufagenin (MBG) and endogenous ouabain (EO) and erythrocyte Na/K-ATPase activity in the absence and in the presence of 3E9 anti-MBG monoclonal antibody (mAb) and Digibind. Levels of MBG and EO were also determined in sham-operated Sprague-Dawley rats and in rats following 4 weeks of PNx. RESULTS: In 25 patients with CKD plasma, MBG but not EO was increased (0.86 ± 0.07 versus 0.28 ± 0.02 nmol/L, P < 0.01) and erythrocyte Na/K-ATPase was inhibited (1.24 ± 0.10 versus 2.80 ± 0.09 μmol Pi/mL/h, P < 0.01) as compared to that in 19 healthy subjects. Ex vivo, 3E9 mAb restored Na/K-ATPase in erythrocytes from patients with CKD but did not affect Na/K-ATPase from control subjects. Following chromatographic fractionation of uremic versus normal plasma, a competitive immunoassay based on anti-MBG mAb detected a 3-fold increase in the level of endogenous material having retention time similar to that seen with MBG. A similar pattern of CTS changes was observed in uremic rats. As compared to sham-operated animals, PNx rats exhibited 3-fold elevated levels of MBG but not that of EO. CONCLUSIONS: In chronic renal failure, elevated levels of a bufadienolideCTS, MBG, contribute to Na/K-ATPase inhibition and may represent a potential target for therapy.
Authors: Olga V Fedorova; Natalia I Tapilskaya; Anton M Bzhelyansky; Elena V Frolova; Elena R Nikitina; Vitaly A Reznik; Vladimir A Kashkin; Alexei Y Bagrov Journal: J Hypertens Date: 2010-02 Impact factor: 4.844
Authors: Valentina V Ishkaraeva-Yakovleva; Olga V Fedorova; Nelly G Solodovnikova; Elena V Frolova; Anton M Bzhelyansky; Igor V Emelyanov; C David Adair; Irina E Zazerskaya; Alexei Y Bagrov Journal: Reprod Sci Date: 2012-05-30 Impact factor: 3.060
Authors: Olga V Fedorova; Valentina I Zernetkina; Victoria Y Shilova; Yulia N Grigorova; Ondrej Juhasz; Wen Wei; Courtney A Marshall; Edward G Lakatta; Alexei Y Bagrov Journal: Circ Cardiovasc Genet Date: 2015-09-15
Authors: Fatimah K Khalaf; Prabhatchandra Dube; Andrew L Kleinhenz; Deepak Malhotra; Amira Gohara; Christopher A Drummond; Jiang Tian; Steven T Haller; Zijian Xie; David J Kennedy Journal: Hypertension Date: 2019-05-28 Impact factor: 10.190
Authors: David J Kennedy; Kevin Shrestha; Brendan Sheehey; Xinmin S Li; Anuradha Guggilam; Yuping Wu; Michael Finucan; Alaa Gabi; Charles M Medert; Kristen Westfall; Allen Borowski; Olga Fedorova; Alexei Y Bagrov; W H Wilson Tang Journal: Circ Heart Fail Date: 2015-08-14 Impact factor: 8.790
Authors: Steven T Haller; David J Kennedy; Amjad Shidyak; George V Budny; Deepak Malhotra; Olga V Fedorova; Joseph I Shapiro; Alexei Y Bagrov Journal: Am J Hypertens Date: 2012-03-01 Impact factor: 2.689